Leiomyosarcoma (LMS) is a soft tissue sarcoma of smooth muscle origin that can arise in
multiple anatomical sites and is broadly classified as extra-uterine LMS or uterine LMS …

FRA1 (FOSL1) is a transcription factor and a member of the activator protein-1 superfamily.
FRA1 is expressed in most tissues at low levels, and its expression is robustly induced in …

First and further-line multidisciplinary treatment of retrop... : Current Opinion in Oncology First
and further-line multidisciplinary treatment of retroperitoneal sarcomas : Current Opinion in …

Background Advanced and unresectable bone and soft tissue sarcomas (BSTS) still
represent an unmet medical need. We demonstrated that the alkylating agent trabectedin …

Simple Summary The 20–30% of locally advanced rectal cancer patients undergoing
preoperative concurrent chemoradiotherapy had no expected efficacy, and ERCC1 …

Clinical responses to anticancer therapies in advanced soft tissue sarcoma (STS) are
unluckily restricted to a small subgroup of patients. Much of the inter-individual variability in …

PURPOSE Literature evidence suggests that trabectedin monotherapy is effective in patients
with recurrent ovarian cancer (OC) presenting BRCA mutation and/or BRCAness phenotype …

HMGA1 is a structural epigenetic chromatin factor that has been associated with tumor
progression and drug resistance. Here, we reported the prognostic/predictive value of …

Metastatic soft-tissue sarcomas (mSTS) encompass a highly heterogeneous group of rare
tumours characterized by different clinical behaviours and outcomes. Currently, prognostic …

Background/Aim: Trabectedin is used as a treatment for advanced-stage soft tissue
sarcomas (STSs), particularly liposarcoma and leiomyosarcoma. Aside from its direct effect …